Kostas Biliouris
Stock Analyst at Oppenheimer
(1.09)
# 3,849
Out of 5,124 analysts
63
Total ratings
34%
Success rate
-14.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kostas Biliouris
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNTA Centessa Pharmaceuticals | Maintains: Outperform | $40 → $62 | $23.69 | +161.71% | 7 | Dec 10, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $50 | $21.31 | +134.63% | 9 | Sep 22, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $450 → $470 | $400.17 | +17.45% | 6 | Sep 8, 2025 | |
| IONS Ionis Pharmaceuticals | Upgrades: Outperform | $40 → $70 | $79.67 | -12.14% | 3 | Sep 3, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Market Perform | $15 → $4 | $1.84 | +117.39% | 1 | Jul 8, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Outperform | $30 → $8 | $3.46 | +131.21% | 2 | May 28, 2025 | |
| RNA Avidity Biosciences | Initiates: Outperform | $72 | $72.10 | -0.14% | 1 | Mar 12, 2025 | |
| DYN Dyne Therapeutics | Initiates: Outperform | $50 | $18.50 | +170.27% | 1 | Mar 12, 2025 | |
| SLN Silence Therapeutics | Maintains: Outperform | $67 → $25 | $6.15 | +306.50% | 2 | Mar 4, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $70 → $50 | $9.21 | +442.89% | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $4.10 | +729.27% | 3 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $17 | $1.67 | +917.96% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $40 | $7.32 | +446.45% | 4 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 | $21.51 | +318.41% | 3 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 | $8.05 | +1,390.68% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 | $27.14 | +110.02% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $37 | $78.24 | -52.71% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $100 | $59.45 | +68.21% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $3.53 | +438.24% | 1 | Oct 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $98 | $53.77 | +82.26% | 1 | Jun 17, 2022 |
Centessa Pharmaceuticals
Dec 10, 2025
Maintains: Outperform
Price Target: $40 → $62
Current: $23.69
Upside: +161.71%
Sarepta Therapeutics
Sep 22, 2025
Upgrades: Outperform
Price Target: $50
Current: $21.31
Upside: +134.63%
Alnylam Pharmaceuticals
Sep 8, 2025
Maintains: Outperform
Price Target: $450 → $470
Current: $400.17
Upside: +17.45%
Ionis Pharmaceuticals
Sep 3, 2025
Upgrades: Outperform
Price Target: $40 → $70
Current: $79.67
Upside: -12.14%
Jasper Therapeutics
Jul 8, 2025
Downgrades: Market Perform
Price Target: $15 → $4
Current: $1.84
Upside: +117.39%
Rocket Pharmaceuticals
May 28, 2025
Maintains: Outperform
Price Target: $30 → $8
Current: $3.46
Upside: +131.21%
Avidity Biosciences
Mar 12, 2025
Initiates: Outperform
Price Target: $72
Current: $72.10
Upside: -0.14%
Dyne Therapeutics
Mar 12, 2025
Initiates: Outperform
Price Target: $50
Current: $18.50
Upside: +170.27%
Silence Therapeutics
Mar 4, 2025
Maintains: Outperform
Price Target: $67 → $25
Current: $6.15
Upside: +306.50%
Intellia Therapeutics
Jan 10, 2025
Maintains: Outperform
Price Target: $70 → $50
Current: $9.21
Upside: +442.89%
Jan 10, 2025
Upgrades: Outperform
Price Target: $34
Current: $4.10
Upside: +729.27%
Aug 15, 2024
Maintains: Outperform
Price Target: $22 → $17
Current: $1.67
Upside: +917.96%
Jul 18, 2024
Maintains: Outperform
Price Target: $63 → $40
Current: $7.32
Upside: +446.45%
Jul 3, 2024
Maintains: Outperform
Price Target: $90
Current: $21.51
Upside: +318.41%
May 15, 2024
Maintains: Outperform
Price Target: $120
Current: $8.05
Upside: +1,390.68%
Mar 27, 2024
Maintains: Outperform
Price Target: $57
Current: $27.14
Upside: +110.02%
Jan 31, 2024
Initiates: Market Perform
Price Target: $37
Current: $78.24
Upside: -52.71%
Nov 3, 2023
Maintains: Outperform
Price Target: $102 → $100
Current: $59.45
Upside: +68.21%
Oct 9, 2023
Initiates: Outperform
Price Target: $19
Current: $3.53
Upside: +438.24%
Jun 17, 2022
Initiates: Outperform
Price Target: $98
Current: $53.77
Upside: +82.26%